| Description |
Unoprostone, a prostaglandin F2α analogs (PGAs), activates BK channels to reduce oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction. Unoprostone reduces intraocular pressure and is used topically for glaucoma or ocular hypertension[1].
|
| Related Catalog |
|
| In Vitro |
Pretreatment with Unoprostone (0.01, 0.1, 1 μM; 1 h before H2O2 treatment) protects against H2O2-induced cell death in a concentration-dependent manner and the effect is significant at 0.1 μM and 1 μM concentrations[1]. Pretreatment with Unoprostone at concentrations of 0.1 to 3 μM protects against light-induced cell death in a concentration-dependent manner; the effect is significant at the 1 and 3 μM concentrations. Unoprostone reduces the morphological change, and it significantly inhibits the low mitochondrial membrane potential and cell death induced by light irradiation[1]. Unoprostone has prostaglandin F2α receptors (FP) binding affinity with a Ki of 3.86 μM[2]. Cell Viability Assay[1] Cell Line: H2O2-induced photoreceptor cell Concentration: 0.01, 0.1, 1 μM Incubation Time: 1 hour before H2O2 treatment Result: Protected against H2O2-induced cell death in a concentration-dependent manner.
|
| In Vivo |
Unoprostone (0.06%, 0.12%; topical instillation; 3 µl) reduces mouse intraocular pressure (IOP) in a dose-dependent manner[3]. Animal Model: Male mice (6 weeks old)[3] Dosage: 0.06%, 0.12% Administration: Topical instillation; 3 µl Result: Reduced mouse IOP in a dose-dependent manner.
|
| References |
[1]. Tsuruma K, et al. Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytoticdysfunction, by activating BK channels. Mol Vis. 2011;17:3556-65. Epub 2011 Dec 30. [2]. Kelly CR, et al. Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and otheranalogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmacol Exp Ther. 2003 Jan;304(1):238-45. [3]. Ota T, et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63.
|
